Home Ubiquitin E3 ligase Ligand chemical - TNF-alpha inhibitor - E3 Ligase inhibitor - Apoptosis related activator Pomalidomide For research use only.

Pomalidomide

Synonyms: CC-4047

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Pomalidomide Chemical Structure

Pomalidomide Chemical Structure

CAS: 19171-19-8

Selleck's Pomalidomide has been cited by 101 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

Related compound libraries

Choose Selective E3 ligase Ligand Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 Cytotoxicity Assay 10 μM 24 h potently augments direct and indirect MM cell killing by SAR 26338273
J-CD38 Cytotoxicity Assay 10 μM 24 h potently augments direct and indirect MM cell killing by SAR 26338273
R-CD38 Cytotoxicity Assay 10 μM 24 h potently augments direct and indirect MM cell killing by SAR 26338273
BC-3 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=107 nM, inhibits cell IC50=107 nM, viability dose dependently 26119939
BCBL-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=74 nM, inhibits cell viability dose dependently 26119939
JSC-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=34 nM, inhibits cell viability dose dependently 26119939
VG-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=101 nM, inhibits cell viability dose dependently 26119939
UMPEL-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=32 nM, inhibits cell viability dose dependently 26119939
UMPEL-3 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=111 nM, inhibits cell viability dose dependently 26119939
BC-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=744 nM, inhibits cell viability dose dependently 26119939
BCP-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=396 nM, inhibits cell viability dose dependently 26119939
APK-1 Growth Inhibition Assay 39-1250 nM 5 d DMSO  IC50=226 nM, inhibits cell viability dose dependently 26119939
RPMI8226  Growth Inhibition Assay 0.01-50 μM 48 h DMSO  IC50=8 μM 26097872
OPM2  Growth Inhibition Assay 0.01-50 μM 48 h DMSO  IC50=10 μM 26097872
RPMI8226  Function Assay 10 μM 48 h DMSO  strengthens cytoplasmic-nuclear shuttling of mTOR and p-mTOR protein 26097872
OPM2  Function Assay 10 μM 48 h DMSO  strengthens cytoplasmic-nuclear shuttling of mTOR and p-mTOR protein 26097872
RPMI8226 Function Assay 0.1-10 μM 4 h DMSO  increases VEGF mRNA expression 25053990
SH-SY5Y  Apoptosis Assay 25 μg/mL 1 h causes statistically significant reduction in both CPF- and CPF+CM-induced apoptosis  24975276
JJN3 Growth Inhibition Assay 0.1-100 μM 72 h DMSO inhibits cell growth slightly 23178378
XG-1 Growth Inhibition Assay 0.1-100 μM 72 h DMSO inhibits cell growth 23178378
CD138+  Growth Inhibition Assay 0.1-100 μM 72 h DMSO inhibits cell growth 23178378
XG-1 Function Assay 2/100 μM 24 h DMSO inhibits CCL3/MIP-1α mRNA expression 23178378
U266 Growth Inhibition Assay 0.01-10 μM 48 h DMSO inhibits cell growth dose dependently 22552008
CRBN60 Growth Inhibition Assay 0.01-10 μM 48 h DMSO inhibits cell growth dose dependently 22552008
CRNB75 Growth Inhibition Assay 0.01-10 μM 48 h DMSO inhibits cell growth dose dependently 22552008
MM.1S Growth Inhibition Assay 0.01-10 μM 48 h DMSO significantly inhibits proliferation at concentrations as low as 0.01μM 21389327
OPM2 Growth Inhibition Assay 0.01-10 μM 48 h DMSO significantly inhibits proliferation at concentrations as low as 0.01μM 21389327
MM.1S Function Assay 10 μM 72 h DMSO significantly decreases the protein level of C/EBPβ isoforms  21389327
H929 Function Assay 10 μM 72 h DMSO significantly decreases the protein level of C/EBPβ isoforms  21389327
OPM2 Function Assay 10 μM 72 h DMSO significantly decreases the protein level of C/EBPβ isoforms  21389327
CT26 Function Assay 1/10 μM 24 h reduces the numbers of live colonies  19638977
T-cells Function assay 2 to 3 days Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA, EC50 = 0.008 μM. 23168019
DF15 Function assay 4 hrs Induction of cereblon-mediated aiolos degradation in human DF15 cells expressing ePL-tagged aiolos after 4 hrs by luminometric analysis, EC50 = 0.022 μM. 28425720
DF15 Function assay 4 hrs Induction of cereblon-mediated ikaros degradation in human DF15 cells expressing ePL-tagged ikaros after 4 hrs by luminometric analysis, EC50 = 0.024 μM. 28425720
DF15 Function assay 4 hrs Induction of CRL4/CRBN ubiquitin ligase-mediated aiolos degradation in human DF15 cells expressing pLOC-ePL-tagged aiolos after 4 hrs by luminescence based beta-galactosidase enzyme fragmentation complementation assay, EC50 = 0.027 μM. 28358507
NAMALWA Antiproliferative assay 72 hrs Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting, IC50 = 0.03 μM. 23168019
HeLa Function assay Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation, IC50 = 1.27 μM. 17845850
DF15 Function assay 0.01 to 1 uM 5 hrs Induction of cereblon-mediated aiolos degradation in human DF15 cells at 0.01 to 1 uM after 5 hrs by immunoblot analysis 28425720
OPM2 Function assay 0.01 to 1 uM 5 hrs Induction of cereblon-mediated ikaros degradation in human OPM2 cells at 0.01 to 1 uM after 5 hrs by immunoblot analysis 28425720
DF15 Function assay 0.01 to 1 uM 5 hrs Induction of cereblon-mediated ikaros degradation in human DF15 cells at 0.01 to 1 uM after 5 hrs by immunoblot analysis 28425720
OPM2 Function assay 0.01 to 1 uM 5 hrs Induction of cereblon-mediated aiolos degradation in human OPM2 cells at 0.01 to 1 uM after 5 hrs by immunoblot analysis 28425720
Click to View More Cell Line Experimental Data

Biological Activity

Description Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
Targets
CRBN [5] TNF-α [1]
(PBMCs)
13 nM
In vitro
In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]
Kinase Assay Inhibition of TNF-α synthesis
TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
Cell Research Cell lines Raji, SU-DHL-4 and SU-DHL-10 cell lines
Concentrations Dissolved in DMSO, final concentrations 2.5-40 μg/mL
Incubation Time 24 or 48 hours
Method

For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.
Experimental Result Images Methods Biomarkers Images PMID
Western blot IKZF1 / IKZF3 / UBE2G1 / CRBN CEBPβ 30234487
Immunofluorescence IKZF1 29496670
In Vivo
In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]
Animal Research Animal Models Disseminated lymphoma-bearing SCID mice
Dosages 0.5 mg/kg
Administration Injection i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04902443 Recruiting Viral Associated Malignancies|Kaposi Sarcoma|EBV/KSHV-associated Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 10 2021 Phase 1

Chemical lnformation & Solubility

Molecular Weight 273.24 Formula

C13H11N3O4
CAS No. 19171-19-8 SDF Download Pomalidomide SDF
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 55 mg/mL ( (201.28 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

Answer:
S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

Question 2:
I would like to know if the pomalidomide is racemic or optically active?

Answer:
Our S1567 Pomalidomide is racemic.

Tags: buy Pomalidomide | Pomalidomide supplier | purchase Pomalidomide | Pomalidomide cost | Pomalidomide manufacturer | order Pomalidomide | Pomalidomide distributor